Preoperative staging of mesothelioma by 18F-fluoro-2-deoxy-d-glucose positron emission tomography/computed tomography fused imaging and mediastinoscopy compared to pathological findings after extrapleural pneumonectomy

European Journal of Cardio-thoracic Surgery

Volumn 34, Issue 5, 2008, Pages 1090-1096

  Sørensen, Jens Benn ^a   Ravn, Jesper ^b   Loft, Annika ^c   Brenøe, Jørn ^b   Berthelsen, Anne Kiil ^b,c  

^a FINSEN LABORATORY   (Denmark)

^b Rigshospitalet   (Denmark)

^c PET and Cyclotron Unit   (Denmark)

Author keywords

Extrapleural pneumonectomy; Mediastinoscopy; Mesothelioma; PET CT scan; Staging

Indexed keywords

CARBOPLATIN; FLUORODEOXYGLUCOSE F 18; IOPROMIDE; NAVELBINE; PEMETREXED;

ADULT; AGED; ARTICLE; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; LUNG CANCER; LUNG FUNCTION TEST; LUNG RESECTION; MALE; MEDIASTINOSCOPY; MESOTHELIOMA; MORBIDITY; MORTALITY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MEDIASTINOSCOPY; MESOTHELIOMA; MIDDLE AGED; NEOPLASM STAGING; PNEUMONECTOMY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; UNNECESSARY PROCEDURES;

EID: 55049098906     PISSN: 10107940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcts.2008.07.050     Document Type: Article

References (24)

1. Sørensen J.B. Mesothelioma. In: Hiddemann W., Bartram C.R., and Huber H. (Eds). Die Oncologie. Lehrbuch der Klinischen Oncologie (2004), Berlin-Heidelberg, Germany, Springer-Verlag 1358-1376
2. Evans A.L., and Gleeson F.V. Radiology in pleural disease: state of the art. Respirology 9 (2004) 300-312
3. Wang Z.J., Reddy G.P., Gotway M.B., Higgins C.B., Jablons D.M., Ramaswamy, Hawkins R.A., and Webb R. Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET. RadioGraphics 24 (2004) 105-119
4. Boiselle P.M., Patz Jr. E.F., Vining D.J., Weissleder R., Shepard J.A., and McLoud T.C. Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. RadioGraphics 18 (1998) 1061-1069
5. Maziak D.E., Gagliardi A., Haynes A.E., MacKay J.A., and Evans W.K. Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer 48 (2005) 157-169
6. Sugarbaker D.J., Jaklitsch M.T., Bueno R., Richards W., Lukanich J., Mentzer S.J., Colson Y., Linden P., Chang M., Capalco L., Oldread E., Neragi-Miandoab S., Swanson S.J., and Zellos L.S. Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg 128 (2004) 138-146
7. Opitz I., Kestenholz P., Lardinois D., Müller M., Rousson V., Schneiter D., and Stahel R. Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg 29 (2006) 579-584
8. Rusch V.W., Rosenzweig K., Venkatraman E., Leon L., Raben A., Harrison L., Bains M.S., Downey R.J., and Ginsberg R.J. A phase II trial of surgical resection and adjuvant high dose hemithoracic radiation for malignant pleural mesothelioma. J Thorac Cardiovasc Surg 122 (2001) 788-795
9. Jerusalem G., Hustinx R., Beguin Y., and Fillet G. PET scan imaging in oncology. Eur J Cancer 39 (2003) 1525-1534
10. Haberkorn U. Positron emission tomography in the diagnosis of mesothelioma. Lung Cancer 455 (2004) 573-576
11. 18F-FDG PET for evaluating malignant pleural mesothelioma. Cancer Biother Radiopharmaceut 19 (2004) 149-154
12. Flores R.M. The role of PET in the surgical management of malignant pleural mesothelioma. Lung Cancer 49 S1 (2005) S27-S32
13. von Schulthess G.K., Steinert H.C., and Hany T.F. Integrated PET/CT: current applications and future directions. Radiology 238 (2006) 405-422
14. Rice D.C., Erasmus J.J., Stevens C.W., Vaporciyan A.A., Wu J.S., Tsao A.S., Walsh G.L., Swisher S.G., Hofstetter W.L., Ordonez N.G., and Smythe W.R. Extended surgical staging for potentially resectable malignant pleural mesothelioma. Ann Thorac Surg 80 (2005) 1988-1993
15. Rusch V.W. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 108 (1995) 1122-1128
16. Mountain C.F., and Dresler C.M. Regional lymph node classification for lung cancer staging. Chest 111 (1997) 1718-1723
17. Lardinois D., Weder W., and Hany T.F. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 348 (2003) 2500-2507
18. Flores R.M., Akhurst T., Gonen M., Larson S.M., and Rusch V.W. Positron emission tomography defines metastatic disease but not locoregional disease in patients with malignant pleural mesothelioma. J Thorac Cardiovasc Surg 126 (2003) 11-16
19. Schneider D.B., Clary-Macy C., and Challa S. Positron emission tomography with F18-fluorodexyglucose in the staging and preoperative evaluation of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 120 (2000) 128-133
20. Erasmus J.J., Truong M.T., Smythe W.R., Munden R.F., Marom E.M., Rice D.C., Vaporciyan A.A., Walsh G.L., Sabloff B.S., Broemeling L.D., Stevens C.W., Pisters K.M., Podoloff D.A., and Macapinlac H.A. Integrated computed tomography-positron emission tomography in patients with potentially resectable malignant pleural mesothelioma: staging implications. J Thorac Cardiovasc Surg 129 (2005) 1364-1370
21. Rusch V.W., and Venkatraman E. The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg 111 (1996) 815-825
22. Alvarez J.M., Ha F., Musk W., Robins P., Price R., and Byrne M.J. Importance of mediastinoscopy, bilateral thoracoscopy, and laparoscopy in correct staging of malignant mesothelioma before extrapleural pneumonectomy. J Thorac Cardiovasc Surg 130 (2005) 905-906
23. Baldini E.H., Recht A., Strauss G.M., DeCamp M.M., Swanson S.J., and Liptay M.J. Patterns of failure after trimodality therapy for malignant mesothelioma. Ann Thorac Surg 63 (1997) 334-338
24. Sugarbaker D.J., Flores R.M., Jaklitsch M.T., Richards W.G., Strauss G.M., Corson J.M., DeCamp M.M., Swanson S.J., Bueno R., Lukanich J.M., Baldini E.H., and Mentzer S.J. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 117 (1999) 54-65